Atypical antipsychotics in the treatment of affective symptoms: A review

Annals of Clinical Psychiatry

Volumn 16, Issue 1, 2004, Pages 3-13

  Masan, Prakash S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bipolar disorder; Depression; Mania; Olanzapine; Quetiapine; Risperidone; Ziprasidone

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHOLESTEROL; FLUOXETINE; GLUCOSE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRIACYLGLYCEROL; VALPROATE SEMISODIUM; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACNE; AGRANULOCYTOSIS; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL PRACTICE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INCREASED APPETITE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; POLYDIPSIA; POLYURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; RHINITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; HUMANS; MOOD DISORDERS; PIPERAZINES; RISPERIDONE; THIAZOLES;

EID: 3442884551     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1080/10401230490281410     Document Type: Review

References (64)

1. Peuskens J, Van Baelen B, De Smedt C, Lemmens P: Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 2000; 15:343-349.
2. Tollefson GD, Sanger TM: Anxious-depressive symptoms in schizophrenia: A new treatment target for pharmacotherapy? Schizophr Res 1999; 35(Suppl 3):S13-S21.
3. Glick ID, Suppes T, DeBattista C, Hu RJ, Marder S: Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med 2001; 134:47-60.
4. Nemeroff CB: An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 2000; 61:19-25.
5. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP: The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med 2000; April (Special Report):1-104.
6. Zarate CA, Vemuri M, Cavanagh S, Land M: Atypical antipsychotic drugs in nonschizophrenic psychiatric disorders. Curr Psychiatry Rep 2000; 2:291-297.
7. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (Revision). Am J Psychiatry 2002; 159 (4 Suppl):1-50.
8. Ghaemi SN, Goodwin FK: Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. J Clin Psychopharmacol 1999; 19:354-361.
9. Ghaemi SN: New treatments for bipolar disorder: The role of atypical neuroleptic agents. J Clin Psychiatry 2000; 61(Suppl 14):33-42.
10. Kaplan M: Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry 2000; 61: 388-389.
11. Keck PE, Strakowski SM, McElroy SL: The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61(Suppl 3):4-9.
12. Schweitzer I: Does risperidone have a place in the treatment of nonschizophrenic patients? Int Clin Psychopharmacol 2001; 16:1-19.
13. Worrel JA, Marken PA, Beckman SE, Ruehter VL: Atypical antipsychotic agents: A critical review. Am J Health Syst Pharm 2000; 57:238-255.
14. Bowden CL: Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001; 10:661-671.
15. Glick RL, Ghaemi SN: The emergency treatment of depression complicated by psychosis or agitation. J Clin Psychiatry 2000; 61(Suppl 14):43-48.
16. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993; 13:25-40.
17. Conley RR, Mahmoud R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158:765-774.
18. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835.
19. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry 1997; 58:538-546.
20. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166: 712-726.
21. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams TS: Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996; 153:417-419.
22. Masand PS: Weight gain associated with psychotropic drugs. Exp Opin Pharmacother 2000; 1:377-389.
23. Masand PS, Gupta S: Long-term adverse effects of novel antipsychotics. J Psychiatric Practice 2000; 6: 299-309.
24. Myers JE, Mahmoud R, Berry SA, Conley RR: Risperidone versus olanzapine for the treatment of mood symptoms in patients with schizophrenia or schizoaffective disorder. Presented at: Fourth International Meeting of the College of Psychiatric and Neurologic Pharmacists; March 25-28, 2001; San Antonio, Texas.
25. Segal J, Berk M, Brook S: Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21:176-180.
26. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL: Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159:1146-1154.
27. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A: Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141-147.
28. Yatham LN, Binder C, Riccardelli R, Leblanc J, Connolly M, Kusumakar V: Risperidone in acute and continuation treatment of mania. RIS-CAN 25 Study Group. Int Clin Psychopharmacol 2003; 18:227-235.
29. Zyprexa® (olanzapine) Prescribing Information. Eli Lilly and Company. Indianapolis, IN, USA. Literature revised February 16, 2001.
30. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V: Olanzapine versus placebo in the treatment of acute mania. The Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156:702-709.
31. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A: Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000; 57:841-849.
32. Chengappa KNR, Baker RW, Shao L, Yatham LN, Tohen M, Gershon S, Kupfer DJ: Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord 2003; 5:1-5.
33. Baker RW, Tohen M, Fawcett J, Risser RC, Schuh LM, Brown E, Stauffer VL, Shao L, Tollefson GD: Acute dysphoric mania: Treatment response to olanzapine versus placebo. J Clin Psychopharmacol. 2003; 23:132-137.
34. Berk M, Ichim L, Brook S: Olanzapine compared to lithium in mania: A double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999; 14:339-343.
35. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA: Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159: 1011-1017.
36. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW: A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63:1148-1155.
37. Koller E, Malozowski S, Doraiswamy PM: Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001; 286:2547-2548.
38. Mir S, Taylor D: Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol. 2001; 16:63-73.
39. Muench J, Carey M: Diabetes mellitus associated with atypical antipsychotic medications: New case report and review of the literature. J Am Board Fam Pract. 2001; 14:278-282.
40. Selva KA, Scott SM: Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr. 2001; 138:936-938.
41. Von Hayek D, Huttl V, Reiss J, Schweiger HD, Fuessl HS: [Hyperglycemia and ketoacidosis associated with olanzapine]. Nervenarzt 1999; 70:836-837.
42. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: Metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63:425-433.
43. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. J Clin Psychiatry 2002; 63:920-930.
44. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM: A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216-1223.
45. Chisholm K, Suppes T: Clinical response to quetiapine add-on for treatment refractory bipolar disorder. Abstract presented at the Fourth International Conference on Bipolar Disorder; June 14-16, 2001; Pittsburgh, Pa.
46. Ghaemi SN, Goldberg JF, Ko JY, Oakley L: Seroquel treatment of rapid-cycling bipolar disorder: an open prospective study. Abstract presented at the Fourth International Conference on Bipolar Disorder; June 14-16, 2001; Pittsburgh, Pa.
47. Vieta E, Parramon G, Padrell E, Nieto E, Martinez-Arán A, Corbella B, Colom F, Reinares M, Goikolea JM, Torrent C: Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002; 4:335-340.
48. Keck PE, Reeves KR, Harrigan EP: Ziprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double-blind, placebo-controlled, multicenter studies. Ziprasidone Study Group. J Clin Psychopharmacol 2001; 21:27-35.
49. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K: Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Ziprasidone in Mania Study Group. Am J Psychiatry 2003; 160:741-748.
50. Guille C, Sachs GS, Ghaemi SN: A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61:638-642.
51. Müller-Siecheneder F, Müller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O: Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol. 1998; 18:111-120.
52. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 17:407-418.
53. Myers JE, Mahmoud R, Keith SJ, Berry S, Csernansky JG: Long-term benefit of risperidone versus haloperidol for affective symptoms in patients with schizophrenia and schizoaffective disorder. Presented at: Thirty-ninth Annual Meeting of the American College of Neuropsychopharmacology; December 10-14, 2000; San Juan, Puerto Rico.
54. Tollefson GD, Andersen SW, Tran PV: The course of depressive symptoms in predicting relapse in schizophrenia: A double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999; 46:365-373.
55. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60:256-259.
56. Shelton RC, Addington S, Augenstein E, Ball W: Risperidone and paroxetine in bipolar depression. Presented at the Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, LA.
57. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465.
58. Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250-258.
59. Rothschild AJ, Bates KS, Boehringer KL, Syed A: Olanzapine response in psychotic depression. J Clin Psychiatry 1999; 60:116-118.
60. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131-134.
61. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42:233-246.
62. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG: Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54:549-557.
63. Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J: Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000; 61:185-189.
64. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20:491-505.